Literature DB >> 12115504

CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines.

Katja Pokrovskaja1, Barbro Ehlin-Henriksson, Csaba Kiss, Anita Challa, John Gordon, Peter Gogolak, George Klein, Laszlo Szekely.   

Abstract

Epstein-Barr virus (EBV) drives the proliferation of human B cells in vitro and during primary infection in vivo. The transformed immunoblasts express nuclear proteins EBNA1-6, transcribed from the Cp/Wp promoter, and the membrane proteins LMP-1, -2A and -2B (lymphoblastoid type of latency). EBV persists through life in resting memory B cells with a restricted type of latency in the absence of the Cp/Wp promoter activity. Since CD40 crosslinking can reportedly inhibit the growth of EBV-transformed lymphoblastoid cell lines (LCLs), we have examined the effect of CD40 ligation on the expression of EBNAs and LMP-1 and on Cp EBV promoter activity together with several phenotypic markers. CD40 crosslinking led to a partial downregulation of EBNA-2, EBNA3-6 and LMP-1 in LCLs, paralleled by downregulation of Cp promoter activity. It also induced upregulation of the germinal center marker CD77 on the LCL cells. Our findings suggest that the encounter of proliferating EBV-transformed immunoblasts with CD40L, as would occur when normal B cells generate memory cells in germinal centers, may switch the viral transcription program from the full lymphoblastoid to a more restricted latency program in a proportion of cells. This would permit virus persistence in the B-cell memory compartment. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115504     DOI: 10.1002/ijc.10417

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Authors:  Noémi Nagy; Mónika Adori; Abu Rasul; Frank Heuts; Daniel Salamon; Dorina Ujvári; Harsha S Madapura; Benjamin Leveau; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines.

Authors:  Csaba Kiss; Jun Nishikawa; Kenzo Takada; Pankaj Trivedi; George Klein; Laszlo Szekely
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

3.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

4.  Epstein-Barr virus LMP2A imposes sensitivity to apoptosis.

Authors:  Michelle Swanson-Mungerson; Rebecca Bultema; Richard Longnecker
Journal:  J Gen Virol       Date:  2010-05-19       Impact factor: 3.891

5.  Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research.

Authors:  Lilla Ozgyin; Attila Horvath; Zsuzsanna Hevessy; Balint L Balint
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

6.  Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility.

Authors:  Ali Afrasiabi; Grant P Parnell; Nicole Fewings; Stephen D Schibeci; Monica A Basuki; Ramya Chandramohan; Yuan Zhou; Bruce Taylor; David A Brown; Sanjay Swaminathan; Fiona C McKay; Graeme J Stewart; David R Booth
Journal:  Genome Med       Date:  2019-04-30       Impact factor: 11.117

7.  CD4 + T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes.

Authors:  Semjon Sidorov; Lara Fux; Katja Steiner; Samyo Bounlom; Sabrina Traxel; Tarik Azzi; Arbeneshe Berisha; Christoph Berger; Michele Bernasconi; Felix K Niggli; Yvonne Perner; Sugeshnee Pather; Werner Kempf; David Nadal; Simone Bürgler
Journal:  Cancer Immunol Immunother       Date:  2021-10-19       Impact factor: 6.630

8.  Epstein-Barr virus latency switch in human B-cells: a physico-chemical model.

Authors:  Maria Werner; Ingemar Ernberg; Jiezhi Zou; Jenny Almqvist; Erik Aurell
Journal:  BMC Syst Biol       Date:  2007-08-31

9.  The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.

Authors:  Eahsan Rasul; Daniel Salamon; Noemi Nagy; Benjamin Leveau; Ferenc Banati; Kalman Szenthe; Anita Koroknai; Janos Minarovits; George Klein; Eva Klein
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

10.  Dissecting the contribution of EBNA3C domains important for EBV-induced B-cell growth and proliferation.

Authors:  Hem Chandra Jha; Sanket Kumar Shukla; Jie Lu; Mahadesh Prasad Aj; Shuvomoy Banerjee; Erle S Robertson
Journal:  Oncotarget       Date:  2015-10-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.